

The logo for aditXt, featuring the word 'adit' in a lowercase sans-serif font, followed by 'Xt' in a larger, bold, uppercase sans-serif font. A small 'TM' trademark symbol is positioned to the upper right of the 't'.

aditXt™

A blue-outlined rectangular box with a notch on the top-left corner, containing the main headline text.

MAKING  
PROMISING INNOVATIONS  
**POSSIBLE, TOGETHER**

**AMRO ALBANNA**

Co-Founder, Chairman & CEO

# SAFE HARBOR STATEMENT & DISCLAIMERS

This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, our ongoing and planned product development; our intellectual property position; our ability to develop commercial functions; expectations regarding project launch and revenue; our results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the industry in which we operate; and the trends that may affect the industry or us. Although we have a reasonable basis for each forward-looking statement, we caution that forward-looking statements are not guarantees of future performance.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2023, that was filed with the U.S. Securities and Exchange Commission on April 16, 2024 as well as discussions of potential risk, uncertainties, and other essential factors in the Company's subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

This Presentation includes specific projections and forward-looking statements provided by the Company, including concerning the Company's anticipated future performance and our ability to develop and commercialize products and obtain regulatory approvals. Such projections and forward-looking statements reflect various assumptions of management. They are subject to significant business, regulatory, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company. Accordingly, there can be no assurance that such projections or forward-looking statements will be realized. Actual results may vary from anticipated results, and such variations may be material.

Therefore, you should not rely on these projections or forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the projections or forward-looking statements include, among others: (i) the Company's ability to raise additional capital, which may not be available on acceptable terms, or at all; (ii) the Company's ability to finance and execute on its strategic M& A initiatives; (iii) future sales or issuances of substantial amounts of our common stock, including, potentially as a result of future acquisitions or strategic transactions could result in significant dilution; (iv) we have issued a significant number of shares of convertible preferred stock and warrants and may continue to do so in the future and the conversion and/or exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock; (v) we may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities; (vi) we received the determination from Nasdaq that we regained compliance with the Nasdaq continued listing requirements, however, we remain subject to a panel monitor of our ongoing compliance until December 29, 2024 and if we fail to comply with such requirements during the panel monitor, it could result in the delisting of our securities by Nasdaq; (vii) our ability to enter strategic relationships for development or commercialization of our products; (viii) patents may not issue from our patent applications, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; (ix) our ability to obtain sufficient financing; and (x) our ability to consummate on terms that are favorable to us or at all any potential strategic transactions.

Any projection or forward-looking statement made by Aditxt in this Presentation is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to update any projection or forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.





**AMRO ALBANNA**

Co-founder & CEO



*“Together, we have the power to shape the future of innovation and make a lasting impact on global health.”*

aditXt™

A PUBLIC COMPANY  
(Nasdaq: ADTX)  
WITH A **MISSION** TO  
**ACCELERATE INNOVATIVE**  
BUSINESSES TO ADDRESS  
THE MOST PRESSING  
HEALTH CHALLENGES

© 2024 ADITXT, INC.

# BUSINESS MODEL





# Current and Potential Programs and Subsidiaries

## Adimune - Immune Health

A pre-clinical stage company that develops immune modulation therapies to advance immune health by naturally restoring immune tolerance.

## Pearsanta - Precision Health

A commercial-stage company developing precision diagnostic technologies. Their proprietary platforms include - Mitomic® and Flow Cytometry technologies.

## Women's Health (Proposed Acquisition)

On December 11, 2023, we entered into an Agreement and Plan of Merger with Adifem f/k/a Adicure, Inc., a majority owned subsidiary of the Company and Evofem Biosciences, Inc., pursuant to which we are seeking to acquire Evofem. The closing of the transaction is subject to a number of closing conditions, including Aditxt securing sufficient financing to satisfy its obligations at closing, and approval by Evofem's stockholders. We can provide no assurance that the conditions to closing will be satisfied and that we will ultimately close.

Evofem is the creator of an FDA-approved hormone-free contraceptive gel, Phexxi® and also recently acquired Solosec®, an antimicrobial agent for bacterial vaginosis and trichomoniasis.

## Public Health (Proposed Acquisition)

On April 1, 2024, we entered into an Arrangement Agreement with Adivir, Inc., a wholly owned subsidiary of the Company and Appili Therapeutics, Inc., pursuant to which we are seeking to acquire Appili. The closing of the transaction is subject to a number of conditions, including but not limited to, Aditxt securing sufficient financing to satisfy its obligations at closing, and approval of the transaction by Appili's stockholders. We can provide no assurance that the conditions to closing will be satisfied and that we will ultimately close.

Appili has the following assets in its product pipeline:

Likmez™ is a liquid formulation of metronidazole, a broad-spectrum antibiotic that is normally dispensed in a pill form.

ATI-1701 is a tularemia vaccine program that is fully funded by the U.S. Airforce.

ATI-1801 is a late-stage clinical program for topical treatment of cutaneous leishmaniasis, a painful and potentially disfiguring skin infection.

# GLOBAL LEADERSHIP

Team Locations: Silicon Valley | New York | Richmond



**Amro Albanna**

Innovation & Entrepreneurship  
Co-Founder, Chairman & CEO



**Dr. Shahrokh Shabahang**

Innovation  
Co-Founder, Director & CIO



**Rowena Albanna**

Operations  
COO



**Corinne Pankovcin**

Discovery  
CM&AO



**Thomas Farley**

Finance  
CFO



**Jennifer Lee**

People  
VP of HR and Talent Acquisition



**Mary O'Brien**

Communications  
Head of  
Communications

## INDEPENDENT BOARD MEMBERS



**Brian Brady**

Independent Director and Chair of Audit  
Committee



**Jeffrey Runge** MD, FACEP

Independent Director and Chair  
of Corporate Governance &  
Nominating Committee



**Charles Nelson**

Independent Director and  
Chair of Compensation  
Committee



# CURRENT PROGRAMS AND M&A PIPELINE

---

**OVERVIEW**

Adimune is a pre-clinical stage company developing immune modulation therapies with a mission to advance immune health by naturally restoring immune tolerance, reducing dependency on immunosuppression, and transforming treatment for autoimmune diseases and organ transplantation

**CHALLENGE**

Current treatments for autoimmune diseases and organ transplantation rely on long-term immunosuppression, leading to severe side effects and limited efficacy. This highlights the urgent need for innovative solutions for effective, long-term immune modulation without compromising overall health.

**CURRENT FOCUS AREAS & TAM****Psoriasis<sup>1</sup>**

- Affecting approximately 100 million people worldwide
- Market size valued at USD 25.52 billion in 2023; projected to grow to USD 57.68 billion by 2032

**Type 1 Diabetes (T1D)<sup>2</sup>**

- In 2021, about 8.4 million individuals worldwide with T1D
- Market valued at USD 5.6 billion in 2023; projected to grow to USD 9.4 billion by 2034

**Stiff Person Syndrome (SPS)**

- Rare autoimmune disease of the central nervous system mediated by GAD
- Estimated incidence: ~1 in 1 million individuals

1. <https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600> & Mehrmal S. JJAD  
2. 2021 <https://www.biospace.com/type-1-diabetes-market-estimated-to-reach-usd-9-4-billion-by-2034-impelled-by-increased-utilization-of-artificial-pancreas-systems#:~:text=The%20type%20diabetes%20market,4.84%25%20during%202024%2D2034> & Gregory G. The Lancet 2022

Proprietary Product

**APOPTOTIC DNA IMMUNOTHERAPY™ (ADI-100™)****Technology Overview & Nonclinical Findings**

- ✓ Utilizes nucleic acid technology to deliver signals to induce tolerance using two **DNA molecules:**
  - Encode a protein (BAX) that promotes apoptosis
  - Encode a modified antigen to promote tolerance
- ✓ Mimics natural tolerance mechanisms
- ✓ In nonclinical studies, ADI-100™ has demonstrated significant prolongation of skin allografts, reversal of hyperglycemia in type 1 diabetes (T1D) and amelioration of psoriatic lesions
- ✓ The therapeutic effectiveness of ADI-100™ was not accompanied with any impairment of immune responsiveness against systemic infection, tumor growth or benefits of checkpoint inhibitors

© 2024 ADITXT, INC.





**OVERVIEW**

Pearsanta is a commercial stage company developing technologies to empower individuals to achieve optimal health through precision diagnostics, enabling early disease detection, improving prognosis and monitoring, and ultimately enhancing lifelong well-being.

**CHALLENGE**

Late-stage cancer diagnoses lead to higher mortality rates and increased healthcare costs, highlighting the critical need for advanced early detection methods to improve survival rates and reduce economic burdens.

**CURRENT FOCUS AREAS & TAM****Prostate Cancer<sup>1</sup>**

According to the WHO, there were approximately 1,467,854 new cases of prostate cancer diagnosed worldwide in 2022. The prostate cancer diagnostics market was valued at USD 3.7 billion in 2022 and is projected to grow to USD 11.6 Billion in 2032<sup>1</sup>

**Ovarian Cancer<sup>2</sup>**

In 2022, there were more than 324,603 new cases of ovarian cancer worldwide, making it the 18th most common cancer globally and the 8th most common cancer among women. The ovarian cancer diagnostic market size was valued at around USD 1.54 billion in 2023 and is expected to grow to USD 2.71 billion in 2032<sup>2</sup>

**Endometriosis Testing<sup>3</sup>**

The WHO estimates that 1 in 10 women suffer from endometriosis. The market was valued at approximately \$1.27 billion and is projected to grow to USD 2.01 billion by 2028<sup>3</sup>

- 1 <https://www.gminsights.com/industry-analysis/prostate-cancer-diagnostics-market#:~:text=Prostate%20Cancer%20Diagnostics%20Market%20size%20was%20valued%20at%20USD%203.7,CAGR%20from%202023%20to%202032>
- 2 <https://www.gminsights.com/industry-analysis/ovarian-cancer-diagnostic-market/market-size#:~:text=Ovarian%20Cancer%20Diagnostics%20Market%20size%20was%20valued%20at%20around%20USD,6.6%25%20between%202024%20and%202032> & <https://worldovariancancercoalition.org/about-ovarian-cancer/key-stats/>
- 3 <https://www.researchandmarkets.com/report/endometriosis>  
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276577>

Proprietary Product

**MITOMIC® TECHNOLOGY PLATFORM****Planned Products:**✓ **Mitomic® Endometriosis Test (MET™)**

MET™ is a diagnostic for endometriosis that has demonstrated accuracy in predicting surgical outcomes, significantly reducing the diagnostic delay. Early and precise diagnosis through MET™ leads to timely and effective treatment, improving patient outcomes and quality of life.

✓ **Mitomic® Prostate Test (MPT™)**

MPT™ improves the detection of clinically significant prostate cancer, reducing reliance on PSA testing and its associated false positives and over-diagnosis. Accurately predicts prostate cancer, distinguishing between aggressive and non-aggressive forms, guiding treatment decisions, and reducing unnecessary interventions.

Improves patient outcomes by ensuring only those with clinically significant prostate cancer receive treatment, avoiding side effects of unnecessary procedures.

✓ **Mitomic® Ovarian Cancer Test (MOT™)**

MOT™ is an accurate and non-invasive diagnostic for ovarian cancer and has shown accuracy in detecting ovarian cancer early, which is essential for improving treatment outcomes and survival rates. The test can distinguish between benign and malignant ovarian tumors, thereby guiding appropriate treatment decisions. Early and precise diagnosis through MOT™ can lead to timely and effective treatment, significantly improving patient outcomes and quality of life.



# Proposed Acquisitions

---

# INTRODUCTION

## OVERVIEW

Appili is a commercial-stage company with a mission to advance the treatment of infectious diseases by developing innovative antivirals and vaccines to treat emerging, neglected, and resistant infectious diseases that address unmet medical needs, improve patient outcomes, and enhance global health security.

## CHALLENGE

The COVID-19 pandemic has exposed systemic weaknesses in global health systems, emphasizing the urgent need for robust, resilient health infrastructure. Infectious diseases pose a critical global health challenge that carries significant morbidity and mortality rates. The rise of drug-resistant pathogens, neglected tropical diseases, and the threat of bioterrorism underscore the urgent need for new preventive and therapeutic approaches.

## CURRENT FOCUS AREAS & TAM

### Francisella Tularensis<sup>1</sup>

This pathogen, associated with tularemia, poses significant bioterrorism threats (potentially 1,000 times more infectious than anthrax) and has substantial government interest. The tularemia market is anticipated to reach USD 482.5 million by 2030

### Cutaneous Leishmaniasis<sup>2</sup>

The global cutaneous and systemic leishmaniasis market is projected to grow from USD 368.6 million in 2024 to USD 487.5 million by 2034

### Antimicrobial Infections

<https://www.marketresearchfuture.com/reports/tularemia-market-4120>  
<https://www.factmr.com/report/cutaneous-and-systemic-leishmaniasis-market>

## Proprietary Product

### ✓ LIKMEZ™ Metronidazole Oral Suspension 500MG/5ML Solution

It is the only FDA-approved liquid oral suspension of metronidazole, which solves significant issues for patients who cannot swallow the current tablet formulation. U.S. patent coverage protects the composition and preparation methods through 2039

### ✓ ATI-1701 – Tularemia Vaccine

ATI-1701 is a novel, live-attenuated tularemia vaccine candidate addressing a top-priority biothreat (a Category A pathogen by the National Institutes of Health). It is highly lethal (1,000 times more infectious than anthrax) and has no FDA-approved vaccine

### ✓ ATI-1801 - Topical Treatment for Cutaneous Leishmaniasis (CL)

An easy-to-use topical cream formulation of paromomycin repurposed for CL, which is a common and disfiguring disease without appropriate treatment options. ATI-1801 has potent activity against both New-World and Old-World leishmaniasis species with low clinical risk and positive results in several Phase 2 and 3 studies

# INTRODUCTION

## OVERVIEW

Evofem is a U.S. biopharma company commercializing innovative products to address unmet needs in women's health.

## CHALLENGE

Options are sparse for women who do not want to use hormonal birth control products and would prefer to have more control with on-demand, topical products that do not exert systemic effects and are not impacted by other medications.

## CURRENT THERAPEUTIC AREAS & TAM

### • **Hormone-free contraception<sup>1</sup>**

The U.S. contraceptive market was valued at approximately USD 8.3 billion in 2022 and is projected to grow at 5.16% CAGR.<sup>1</sup> The global contraceptive market is valued at approximately USD 28.86 billion and is forecast to reach USD 47.77 billion by 2030.<sup>2</sup>

### • **Bacterial Vaginosis (BV)<sup>2</sup>**

BV is the most common vaginal condition in women ages 15 to 44. It results from an overgrowth of bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor and discharge. The global BV market is projected to grow from USD 4.06 billion in 2024 to USD 8.92 billion in 2031.<sup>3</sup>

### • **Trichomoniasis<sup>3</sup>**

Trichomoniasis is the most common non-viral STI in the world. The underlying parasite, *Trichomonas vaginalis*, affects both men and women. The global market is forecast to grow from USD 63.2 billion in 2022 to USD 90 billion by 2030.<sup>4</sup>


1. Grandview Research. U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable), And Segment Forecasts, 2022 – 2030.

2. <https://www.transparencymarketresearch.com/women-health-therapeutics-market.html>

3. <https://www.linkedin.com/pulse/bacterial-vaginosis-therapeutics-market-ed6yf/>

4. <https://www.databridgemarketresearch.com/reports/global-trichomoniasis-drugs-market>

## Proprietary Product





• **The only FDA-approved, hormone-free, on-demand prescription contraceptive vaginal gel**



• **FDA-approved, single-dose antimicrobial agent**  
• **Complete course of therapy for bacterial vaginosis and Trichomoniasis**

# THANK YOU

 [engagement@aditxt.com](mailto:engagement@aditxt.com)

 [www.aditxt.com](http://www.aditxt.com)

©2024 ADITXT, INC.